News >

Combined Modality Approach May Benefit Select Patients With Oligometastatic NSCLC

Kristi Rosa
Published: Tuesday, Jun 25, 2019

Daniel Gomez, MD

Daniel Gomez, MD

Researchers’ understanding of the biology of oligometastatic non–small cell lung cancer (NSCLC) continues to evolve, and there is now a basis for more aggressively treating a specific subset of patients with combined modalities, said Daniel Gomez, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication